Abstract
During this year there will be approximately 30 thousand deaths due to prostatic cancer in the United States (1). This mortality rate makes prostatic cancer the second commonest fatal tumor in males of all ages in America (1). Besides a high annual mortality rate, prostatic cancer is now the most commonly diagnosed malignancy in males of all ages in the United States (1). These high annual incidence rates translate into the human reality that one of every 11 American white male will eventually develop clinical prostatic cancer during their lifetime (2). Rates for American black males are even higher such that the lifetime risk for cancer is one out of every 10 (3). In addition, the annual incidence rate of clinical prostatic cancer has increased steadily since 1930’s to the present time (4).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Boring, C., Squires, T. and Tong, T. Cancer Statistics — Cancer Journal for Clinicians 42:19–38, 1992.
Seidman, H., Mushinski, M. H., Gelb, S. K. and Silverberg, E. Probabilities of eventually developing or dying of cancer: United States. Cancer Journal for Clinicians 35:36–56, 1985.
Mettlin, G. Epidemiology of prostate cancer in different population groups. Clinics in Oncology 2:287–300, 1983.
Devesa, S. S. and Silverman, D. T. Cancer incidence and morbidity trends in the United States: 1935-1947. J. Natl. Cancer Inst. 60:545–571, 1978.
Carter, H. B. and Isaacs, J. T. Experimental and theoretical basic for hormonal treatment of prostatic cancer. Seminars in Urology 4:262–268, 1988.
U.S. Bureau of the Census, Statistical Abstract of the United States 1989 (109th edition) Washington, DC, 1989.
Horm, J. and Sondik, E. Person-Years of life lost due to cancer in the United States 1970 and 1984. Am. J. Public Health 79:1490–1493, 1989.
Carter, H. and Coffey, D. Prostate cancer: The magnitude of the problem in the United States. In Coffey, D., Resnick, M., Dorr, F. et. al (eds): A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Plenum Press, New York, Pp. 1–9, 1988.
Carter, H. B., Piantadosi, S. and Isaacs, J. T. Clinical evidence for and implications of the multistep development of prostate cancer. J. Urol. 143:742–746, 1990.
Dhom, G. Classification and grading of prostatic carcinoma. Recent Results Cancer Res 60:14–26, 1977.
Hohbach, C. and Dhom, G. Pathology of prostatic cancer. Scand. J. Urol Nephrol 55:37, 1980.
Watanabe, H., Ohe, H., Inaba, T., Itakura, Y., Saitoh, M. and Nakao, M. A mobile mass screening unit for prostatic disease. Prostate 5:559, 1984.
Zhang, P., Cheng, S., Zhou, Y., He, A., Hu, J., Huang, S. General survey to detect prostatic disease in 1,165 aged males over 60. Chinese J. Geriat. 3:99, 1984.
Miller, G. J. Diagnosis of stage A prostate cancer in the People’s Republic of China. In: A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Edited by D. S. Coffey, M. I. Resnick, F. A. Door, and J. P. Karr. Plenum Press, New York. Pp. 17–24, 1988.
Dunn, J. E. Cancer epidemiology in populations of the United States — with emphasis on Hawaii and California — and Japan. Cancer Res 35:3240, 1975.
Haenszel, W. and Kurihara, M. Studies on Japanese migrants. I. Mortality for cancer and other diseases among Japanese in the United States. J. Natl Cancer Inst. 40; 43, 1968.
Akazaki, K. and Stemmerman, G. N. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J. Natl Cancer Inst. 50:1137, 1973.
Raghavan, D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Seminars in Oncology 15:371–389, 1988.
Scott, W.W., Menon, M. and Walsh, P.C. Hormonal therapy of prostatic cancer. Cancer 45:1929–1936, 1980.
Schulze, H., Isaacs J.T. and Coffey, D. S. A critical review of the concept of total androgen ablation in the treatment of prostatic cancer. IN Murphy GP, Khoury S, Kuss R, Chatelain C, Denis L (eds). Prostate Cancer Part A: Research Endocrine Treatment, and Histopathology. Progress in Clinical and Biological Research Vol. 243A: pp. 1–19. Alan R. Liss, Inc., New York, 1987.
Smith, J. A., Eyse, H.J., Roberts, T. S. and Middleton, R. G. Transphenoidal hypophysectomy in the management of carcinoma of the prostate. Cancer 53:2385–2387, 1984.
Menon, M. and Walsh, P. C. Hormonal therapy for prostatic cancer. In Murphy GP (ed). Prostatic Cancer. Littleton, Mass, PSG Publ. Co., pp 175–200, 1979.
Lepor, H., Ross, A. and Walsh, P. C. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J. Urol. 128:335–340, 1982.
Prout, G. R., Leiman, B., Daly, J.J., Macloughlin, R. A., Griffin, P. P., Young, H. H. Endocrine changes after diethylstilbestrol therapy. Urology 7:148–155, 1976.
Sinha, A. A., Blackhard, C. E., Seal, U. S. A critical analysis of tumor morphology and hormone treatment in the untreated and estrogen treated responsive and refractory human prostatic carcinoma. Cancer 40:2836–2850, 1977.
Isaacs, J. T. and Coffey, D. S. Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 H adenocarcinoma. Cancer Res 41:5070–5075, 1981.
Isaacs, J. T. Cellular factors in the development of resistance to hormonal therapy. In Bruchovsky, N. and Goldie, J. (eds). Drug and Hormone Resistance in Neoplasia. Vol. 1. CRC Press, Boca Raton, Inc. Pp 139-156, 1982.
Ellis, W. J. and Isaacs, J. T. Effectiveness of complete vs partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic carcinoma. Cancer Res 45:6041–6050, 1985.
Redding, T. W. and Schally, A. V. Investigation of the combination of the agonist D-Trp-6-LHRH and the antiandrogen flutamide on the treatment of Dunning R-3327 H prostatic cancer model. The Prostate 6:219–232, 1985.
Kung, T.T., Mingo, G. G., Siegel, M. I., Watnick, A. S. Effect of adrenalectomy, flutamide and leuprolide on the growth of the Dunning R-3327 prostatic carcinomas. The Prostate 12:357–364, 1988.
Isaacs, J. T. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. The Prostate 5:1–18, 1984.
Isaacs, J. T. Relationship between tumor size and curability of prostate cancer by combined chemohormonal therapy. Cancer Res 49:6290–6294, 1989.
Schulze, H., Isaacs, J. and Senge, T. Inability of complete androgen blockage to increase survival of patients with advanced prostatic cancer as compared to standard hormone therapy. J. Urol. 137:909–914, 1987.
Helpap, B., Steins, R. and Bruhl, P. Autoradiographic in vitro investigations of prostatic tissue with C-14 and H-3 thymidine double labelling method. Beitr Pathol. Anal. Allgem. Path. 151:65–72, 1974.
Meyer, J. S., Sufrin, G. and Martin, S. A. S. Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J. Urol. 128:1353–1356, 1982.
Isaacs, J. T. Antagonistic effect of androgen on prostatic cell death. Prostate 5:545–558, 1984.
Kyprianou, N. and Isaacs, J. T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552–562, 1988.
Wyllie, A. H., Kerr, J. F.R. and Currie. A. R. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68:251–306, 1986.
Kerr, J. F. R., Wyllie, A. H. and Currie, A. R. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Brit. J. Cancer 26:239–257, 1972.
Bowen, I. D. and Lockshin, R. A. Cell Death in Biology and Pathology. London: Chapman and Hill, 1981.
Wyllie, A. H. Glucocorticoid induces in thymocytes a nuclease-like activity associated with the chromatin condensation of apoptosis. Nature 284:555–556, 1980.
Umansky, S. R., Korol, B. A. and Nelipovich, P. A. In vivo DNA degradation in thymocytes of-irradiated or hydrocortisone-treated rats. Biochim. Biophys. Acta 655:9–17, 1981.
Wyllie, A. H., Kerr, J. F. R, Macaskill, I. A. M. and Currie, A. R. Adrenocortical cell deletion: the role of ACTH. J. Pathol. 111:85–94, 1973.
Cohen, J. J. and Duke, R. C. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J. Immunol. 132:38–42, 1984.
Wyllie, A. H., Morris, R. G., Smith, A. L., Dunlop, D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J. Pathol. 142:67–77, 1984.
Compton, M. M. and Cidlowski, J. A. Rapid in vivo effects of glucocorticoids on the integrity of rat lymphocyte genomic deoxyribonucleic acid. Endocrinology 118:38–45, 1986.
Kyprianou, N., English, H. F. and Isaacs, J. T. Activation of a Ca+2-Mg+2-dependent endonuclease as an early event in castration-induced prostatic cell death. The Prostate 13:103–118, 1988.
English, H. F., Kyprianou, N. and Isaacs, J. T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. The Prostate 15:233–250, 1989.
Kerr, J. F.R. and Searle, J. Deletion of cells by apoptosis during castrationinduced involution of the rat prostate. Virchow Archiv B 13:87–102, 1973.
Lesser, B. and Bruchovsky, N. The effects of testosterone, 5-dihydrotestosterone and adenosine 3’,5’-monophosphate on cell proliferation and differentiation in rat prostate. Biochim. Biophys. Acta 308:426–437, 1973.
Lee, C. Physiology of castration-induced regression of the rat prostate. Prog. Clin. Biol. Res. 75A:145–159, 1982.
Sanford, M. L., Searle, J. W. and Kerr, J. F. R. Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Pathology 16:406–410, 1984.
Stanisic, T., Sadlowski, R., Lee, C., Grayhack, J. T. Partial inhibition of castrationinduced ventral prostate regression with actinomycin D and cycloheximide. Invest. Urol. 16:19–22, 1978.
Lee, C. and Sensibar, J. A. Protein of the rat prostate: synthesis of new proteins in the ventral lobe during castration-induced regression. J. Urol. 138:903–908, 1985.
Salzman, A. G., Hiipakka, R. A., Chang, C., Liao, S. Androgen repression of the production of a 29 kilodalton protein and its mRNA in the rat ventral prostate. J. Biol. Chem. 262:432–437, 1987.
Montpetit, M. L., Lawless, K. R. and Tenniswood, M. Androgen repressed messages in the rat ventral prostate. The Prostate 8:25–36, 1986.
Buttyan, R., Zaker, Z., Lockshin, R. and Wolgemuth, D. Cascade induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol. Endocrinol. 2:650–657, 1988.
Kyprianou, N. and Isaacs, J. T. Expression of transforming growth factor-B in the rat ventral prostate during castration-induced programmed cell death. Mol. Endocrinol. 3:1515–1522, 1989.
Connor, J., Sawdzuk, I. S., Benson, M. C., Tomashersky, P., OTool, K. M., Olsson, C. A. and Buttyan, R. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. The Prostate 13:119–130, 1988.
Viskochil, D. H., Perry, S. T., Lea, D. A., Stafford, D. W., Wilson, E. M., French, E S. Isolation of two genomic sequences encoding the mr ∼ 1400 subunit of rat prostatein. J. Biol. Chem. 258:8861–8866, 1983.
Martikainen, P. and Isaacs, J. T. An organ culture system for the study of programed cell death in the rat ventral prostate. Endocrinology 127:1258–1267, 1990.
Martikainen, P. and Isaacs, J. T. Role of calcium in the programmed death of rat prostatic glandular cells. The Prostate 17:175–187, 1991.
Kyprianou, N., English, H., and Isaacs., J. T. Programmed cell death during regression of PC-82 human prostatic cancer. Cancer Res. 50:3748–3753, 1990.
van Steenbrugge, G. J., Groen, M., Romijn, J. C. and Schroder. E Biological effects of hormonal treatment regimens on the transplantable human prostate tumor line (PC-82). J. Urol. 131:812–817, 1984.
Kyprianou, N. and Isaacs, J. T. Thymine-less death in androgen-independent prostatic cancer cells. Biochem. Biophys. Res. Comm. 165:73–81, 1989.
Tucker, R. W., Meade-Cobun, K., Loats, H. Measurement of free intracellular calcium (Ca) in fibroblasts. Digital image analysis of Fura 2 fluorescence. In Fiskum, G. (ed), Plenum Publ. Corp. Pp 239-248, 1989.
Martikainen, P., Kyprianou, N., Tucker, R. W. and Isaacs, J. R. Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Research 51:4693–4700, 1991.
Bettuzzi, S., HYiipakka, R. A., Gilna, P., Liao, S. Identification of an androgenrepressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem. J. 257:293–296, 1989.
Sylvester, S. R., Skinner, M. K. and Griswold, M. D. A sulfated glycoprotein synthesized by Sertoli cell and by epididymal cells is a component of the sperm membrane, Biol. Reproduc. 31:1087–1101, 1984.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Isaacs, J.T. (1993). Prostatic Cancer: An Age-Old Problem. In: Yang, S.S., Warner, H.R. (eds) The Underlying Molecular, Cellular and Immunological Factors in Cancer and Aging. Advances in Experimental Medicine and Biology, vol 330. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2926-2_13
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2926-2_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6270-8
Online ISBN: 978-1-4615-2926-2
eBook Packages: Springer Book Archive